Synthesis and preliminary biochemical evaluation of novel derivatives of PCP

Letters in Drug Design and Discovery

Volumn 7, Issue 2, 2010, Pages 79-87

  Linders, Joannes T M ^a   Furlano, David C ^b   Mattson, Mariena V ^c   Jacobson, Arthur E ^c   Rice, Kenner C ^c  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b Prometheus Laboratories   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Bruylants reaction; Conformations; NMDA receptor; PCP binding site; Phencyclidine; Ritter reaction

Indexed keywords

1 (2 ETHYL 1 PHENYLCYCLOHEXYL)PIPERIDINE; 2 ETHYLCYCLOHEXANONE; CYCLOHEXANONE DERIVATIVE; DIZOCILPINE; PHENCYCLIDINE; PHENCYCLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN; CIS TRANS ISOMERISM; DRUG BINDING SITE; DRUG CONFORMATION; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; RAT; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

EID: 77949693067     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018010790225813     Document Type: Article

References (62)

1. Maddox, V.H. In PCP (Phencyclidine): Historical and Current Perspectives, Domino, E.F. Ed. Ann Arbor, MI, 1981, pp. 1-8.
2. Chen, G. In PCP (Phencyclidine): Historical and Current Perspectives, Domino, E.F. Ed. Ann Arbor, MI, 1981, pp. 9-16.
3. McCarthy, D.A. In PCP (Phencyclidine): Historical and Current Perspectives, Domino, E.F. Ed. Ann Arbor, MI, 1981, pp. 17-29.
4. Drug Abuse and Drug Abuse Research, The Third Triennial report to Congress from the Secretary, Department of Health and Human Services, Department of Health and Human Services, Public Health Services, ADAMHA, NIDA, Rockville, MD, 1991, 45-160.
5. Thombs, D.L. A review of PCP abuse trends and perceptions. Public Health Rep. 1989, 104, 325-328.
6. Haerer, M; Kovar, K.-A. Designer drugs - the phencyclidine series. Pharmazie in unserer Zeit, 1994, 23, 52-61.
7. Johnson, K.M.; Jones, S.M. Neuropharmacology of phencyclidine: basic mechanisms and therapeutic potential. Annu. Rev. Pharmacol. Toxicol., 1990, 30, 707-750.
8. (a) Ritz, M.C.; Lamb, R.J.; Goldberg, S.R.; Kuhar, M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science, 1987, 237, 1219-1223;
9. (b) Seeman, P.; Guan, H.-C.; Hirbec, H. Dopamine D2 high affinity receptor stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. Synapse, 2009, 63, 698-704.
10. (a) Anis, N.A.; Barry, S.C.; Burton, N.R. Lodge, D. The dissociative anesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurons by N-methyl-aspartate. Br. J. Pharmacol., 1983, 79, 565-575;
11. (b) Lodge, D.; Aram, J.A.; Church, J.; Davies, S.N.; Martin, D.; Millar, J.; Zeman, S. In Excitatory Amino Acids in Health and Disease; Lodge, D. Ed., Chichester, 1988, pp. 237-250.
12. Gee, K.R.; Barmettler, P.; Rhodes, M.R.; McBurney, R.N.; Reddy, N.L.; Hu, L.-Y.; Cotter, R.E.; Hamilton, P.N.; Weber, E.; Keana, J.F.W. 10,5-(Iminomethano)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene and derivatives. Potent PCP receptor ligands. J. Med. Chem., 1993, 36, 1938-1946.
13. (a) Jacobson, A.E.; Harrison, E.A.; Mattson, M.V.; Rafferty, M.F.; Rice, K.C.; Woods, J.H.; Winger, G.; Solomon, R.E.; Lessor, R.A.; Silverton, J.V. Enantiomeric and diastereomeric dioxadrols: behavioral, biochemical and chemical determination of the configuration necessary for phencyclidine-like properties. J. Pharmacol. Exp. Ther., 1987, 243, 110-117;
14. (b) Sax, M.; Ebert, K.; Schepmann, D. Wibbeling, B.; Wünsch, B. Synthesis and NMDAreceptor affinity of 4-oxo-dexoxadrol derivatives. Bioorg. Med. Chem., 2006, 14, 5955-5962.
15. Thurkauf, A.; Zenk, P.C.; Balster, R.L.; May, E.L.; George, C.; Carroll, F.I.; Mascarella, S.W.; Rice, K.C.; Jacobson, A.E.; Mattson, M.V. Synthesis, absolute configuration, and molecular modeling study of etoxadrol, a potent phencyclidine-like agonist. J. Med. Chem., 1988, 31, 2257-2263.
16. Kloog, Y.; Haring, R.; Sokolovsky, M. Kinetic characterization of the phencyclidine-N-methyl-D-aspartate receptor interaction: evidence for a steric blockade of the channel. Biochemistry, 1988, 27, 843-848.
17. Huettner, J.E.; Bean, B.P. Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels. Proc. Natl. Acad. Sci. USA, 1988, 85, 1307-1311.
18. Quirion, R.; Chicheportiche, R.; Contreras, P.C.; Johnson, K.M.; Lodge, D, Tam, S.W.; Woods, J.H.; Zukin, S.R. Classification and nomenclature of phencyclidine and sigma receptor sites. Trends Neurosci., 1987, 10, 444-446.
19. Lodge, D.; Collingridge, G. Eds., The Pharmacology of Excitatory Amino Acids; Cambridge, UK, 1990.
20. Kozikowski, A.P. Ed., Neurobiology of the NMDA Receptor; VCH Publishers, New York, 1991.
21. Adler, C.M.; Malhotra, A.K.; Elman, I.; Goldberg, T.; Egan, M.; Pickar, D.; Breier, A. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am. J. Psychiatry, 1999, 156, 1646-1649.
22. Allen, R.M.; Young, S.R. Phencyclidine-induced psychosis. Am. J. Psychiatry, 1978, 135, 1081-1084.
23. Jentsch, J.D.; Roth, R.H. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology, 1999, 20, 201-225.
24. Morris, B.J.; Cochran, S.M.; Pratt, J.A. PCP: from pharmacology to modelling schizophrenia. Curr. Opin. Pharmacol., 2005, 5, 101-106.
25. Bubeníková-Valesová, V.; Horácek, J.; Vrajová, M.; Höschl, C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci. Biobehav. Rev., 2008, 32, 1014-1023.
26. Waterhouse, R.N. Imaging the PCP site of the NMDA ion channel. Nucl. Med. Biol., 2003, 30, 869-878.
27. Ahmadi, A.; Khalili, M.; Abbassi, S.; Javadi, M.; Mahmoudi, A. ; Hajikhani, R. Synthesis and study on analgesic effects of 1-[1-(4-methylphenyl) (cyclohexyl)]-4-piperidinol and 1-[1-(4-methoxyphenyl)(cyclohexyl)]-4- piperidinol as two new phencyclidine derivatives. Arzneimittelforschung, 2009, 59, 202-206.
28. Manoharan, M.; Eliel, E.L.; Kenan, W.R. Carroll, F.I. Large temperature and solvent effects in the conformational equilibrium of phencyclidine [1-phenyl-1-(N-piperidyl)cyclohexane]. Tetrahedron Lett., 1983, 24, 1855-1858 and references 8 and 9 herein.
29. Eaton, T.A.; Houk, K.N.; Watkins, S.F. Fronczek, F.R. Geometries and conformational processes in phencyclidine and a rigid adamantyl analog: variable-temperature NMR, x-ray crystallographic, and molecular mechanics studies. J. Med. Chem., 1986, 26, 479-492.
30. Singh, P.; Jones, L.A.; Couch, R. Structure of 1-(1-phenylcyclohexyl) piperidine (PCP). Acta Crystallogr., 1988, C44, 1976-1979.
31. Argos, P; Barr, R.E. Weber, A.H. Crystal and molecular structure of 1-(1-phenylcyclohexyl)piperidine hydrochloride. Acta Cryst., 1970, B26, 53-61.
32. (a) Kamenka, J.M.; Geneste, P. In Phencyclidine Relat. Arylcyclohexylamines: Present Future Appl., Proc. Jt. Fr.-US Semin. Chem., Pharmacol., Present Future Ther. Appl. Drug Abuse Aspects Arylcyclohexylamines, Kamenka, J.M.; Domino, E.F.; Geneste, P., Eds., 1983, pp. 1-12,
33. (b) Chen, C.; Kozikowski, A.P.; Wood, P.L.; Reynolds, I.J.; Ball, R.G.; Pang, Y.P.. Synthesis and biological activity of 8a-phenyldecahydroquinolines as probes of PCP's binding conformation. A new PCP-like compound with increased in vivo potency. J. Med. Chem., 1992, 35, 1634-1638;
34. (c) Kamenka, J.M.; Michaud, M.; Geneste, P.; Vignon, J.; Chicheportiche, R. Studies on the conformational and biochemical differences between phencyclidine and ketamine. Eur. J. Med. Chem., 1985, 20, 419-424.
35. Geneste, P.; Kamenka, J.-M.; Ung, S.N.; Hermann, P.; Goudal, R.; Trouiller, G. Conformational determination of phencyclidine derivatives in view of structure-activity correlation. Eur. J. Med. Chem., 1979, 14, 301-308.
36. Thurkauf, A.; Hillery, P.; Mattson, M.V.; Jacobson, A.E.; Rice, K.C. Synthesis, pharmacological action, and receptor binding affinity of the enantiomeric 1-(1-phenyl-3-methylcyclohexyl)piperidines. J. Med. Chem., 1988, 31, 1625-1628.
37. Marwaha, J.; Palmer, M.; Hoffer, B.; Freedman, R.; Rice, K.C.; Paul. S.; Skolnick., P. Differential electrophysiological and behavioral responses to optically active derivatives of phencyclidine. Naunyn-Schmiedeberg's Arch. Pharmacol., 1981, 315, 203-209.
38. Iorio, M.A.; Tomassini, L.; Mattson, M.V.; George, C.; Jacobson, A.E. Synthesis, stereochemistry, and biological activity of the 1-(1-phenyl-2- methylcyclohexyl)piperidines and the 1-(1-phenyl-4-methylcyclohexyl) piperidines. Absolute configuration of the potent trans-(-)-1-(1-phenyl- 2-methylcyclohexyl)piperidine. J. Med. Chem., 1991, 34, 2615-2623.
39. Michaud, M.; Warren, H.; Drian, M.J.; Rambaud, J.; Cerruti, P.; Nicolas, J.P.; Vignon, J.; Privat, A., Kamenka, J.-M. Homochiral structures derived from 1-[1-(2-thienyl)cyclohexyl]piperidine (TCP) are potent noncompetitive antagonists of glutamate at NMDA receptor sites. Eur. J. Med. Chem., 1994, 29, 869-876.
40. Mitha, A.P.; Maynard, K.I. Gacyclidine (Beaufour-Ipsen). Curr. Opin. Invest. Drugs, 2001, 2, 814-819.
41. (a) De Costa, B.R.; George, C.; Burke, T.R., Jr.; Rafferty, M.F.; Contreras, P.C.; Mick, S.J.; Jacobson, A.E.; Rice, K.C. Synthesis, configuration, and evaluation of two conformationally restrained analogs of phencyclidine. J. Med. Chem., 1988, 31, 1571-1575.
42. (b) De Costa, B.R.; Mattson, M.V.; George, C.; Linders, J.T.M. Synthesis, configuration, and activity of isomeric 2-phenyl-2-(N-piperidinyl)bicyclo[3.1. 0]hexanes at phencyclidine and σ-binding sites. J. Med. Chem., 1992, 35, 4704-4712.
43. Thompson, W.J., Anderson, P.S.; Britcher, S.F.; Lyle, T.A.; Thies, E.; Magill, C.A., Varga, S.L. Schwering, J.E.; Lyle, P.A.; Christy, M.E.; Evans, B.E.; Colton, C.D.; Holloway, M.K.; Springer, J.P.; Hischfield, J.M.; Ball, R.G.; Amato, J.S.; Larsen, R.D.; Wong, E.H.F.; Kemp, J.A.; Tricklebank, M.D.; Singh, L.; Oles, R.; Priestly, T.; Marshall, G.R.; Knight, A.R.; Middlemiss, D.N., Woodruss, G.N.; Iversen, L.L. Synthesis and pharmacological evaluation of a series of dibenzo[a,d]cycloalkenimines as N-methyl-D-aspartate antagonists. J. Med. Chem., 1990, 33, 789-808.
44. Monn, J.A., Thurkauf, A., Mattson, M.V., Jacobson, A.E.; Rice, K.C. Synthesis and structure-activity relationship of C5-substituted analogs of (±)-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine [(±)-desmethyl-MK801]: ligands for the NMDA receptor-coupled phencyclidine binding site. J. Med. Chem., 1990, 33, 1069-1076.
45. Kroemer, R.T.; Koutsilieri, E.; Hecht, P, Liedl, K.R.; Riederer, P.; Kornhüber, J. Quantitative analysis of the structural requirements for blockade of the N-methyl-D-aspartate receptor at the phencyclidine binding site. J. Med. Chem., 1998, 41, 393-400.
46. Jacobson, A.E.; Linders, J.T.M.; Mattson, M.V.; George, C.; Iorio, M.A. In Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection? Kamenka, J.-M.; Domino, E.F., Eds., NPP Books, Ann Arbor MI, 1992, pp. 61-74.
47. Bigge, C.F.; Malone, T.C.; Hays, S.J.; Johnson, G.; Novak, P.M.; Lescosky, L.J.; Retz, D.M.; Ortwine, D.F.; Probert Jr., A.W.; Coughenour, L.L.; Boxer, P.A.; Robichaud, L.J.; Brahce, L.J.; Shillis, J.L. Synthesis and pharmacological evaluation of 4a-phenanthrenamine derivatives acting at the phencyclidine binding site of the N-methyl-D-aspartate receptor complex. J. Med. Chem., 1993, 36, 1977-1995.
48. Maddox, V.H.; Godefroi, E.F.; Parcell, R.F. The synthesis of phencyclidine and other 1-arylcyclohexylamines. J. Med. Chem., 1965, 8, 230-235.
49. Kamenka, J.-M.; Privat, A.; Chicheportice, R.; Costentin, J. Preparation of 1-aryl-1-piperidinocyclohexanes and analogs as antidepressants and nervous system stimulants. Eur. Pat. Appl., 1991, EP406111.
50. (a) Ward, D.; Kalir, A.; Trevor, A.; Adams, J., Baillie, T.; Castagnoli, N., Jr. Metabolic formation of iminium species: the metabolism of phencyclidine. J. Med. Chem. 1982, 25, 492-494;
51. (b) Hoag, M.K.P.; Trevor, A.J.; Kalir, A.; Castagnoli, N., Jr. Drug Metab. Dispos., 1987, 15, 485-490.
52. Kamenka, J.-M.; Chiche, B.; Goudal, R.; Geneste, P.; Vignon, J.; Vincent, J.P.; Lazdunski, M. Chemical synthesis and molecular pharmacology of hydroxylated 1-(1-phenylcyclohexyl)piperidine derivatives. J. Med. Chem., 1982, 25, 431-435.
53. Lyle, T.A.; Magill, C.A.; Britcher, S.F.; Denny, G.H.; Thompson, W.J.; Murphy, J.S.; Knight, A.R.; Kemp, J.A.; Marshall, G.R.; Middlemiss, D.N.; Wong, E.H.F.; Anderson, P.S. Structure and activity of hydrogenated derivatives of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801). J. Med. Chem., 1990, 33, 1047-1052.
54. Beguin, C.G.; Deschamps, M.-N.; Boubel, V.; Delpuech, J.-J. Carbon-13 nuclear magnetic resonance spectroscopy of methyl-substituted piperidines and their hydrochloride salts. Org. Magn. Res., 1978, 11, 418-423.
55. Kozikowski, A.P.; Pang, Y.-P. Structural determinants of affinity for the phencyclidine binding site of the N-methyl-D-aspartate receptor complex: discovery of a rigid phencyclidine analog of high binding affinity. Mol. Pharmacol., 1990, 37, 352-357.
56. Hays, S.J.; Novak, P.M.; Bigge, C.F.; Colbry, N.L.; Johnson, G.; Lescosky, L.J.; Malone, T.C.; Michel, A.; Ortwine, D.F.; Reily, M.D.; Coughenour, L.L.; Brahce, L.J.; Shillis, J.L.; Probert, A., Jr. Synthesis and pharmacological evaluation of hexahydrofluorenamines as noncompetitive antagonists at the N-methyl-D-aspartate receptor. J. Med. Chem., 1993, 36, 654-670.
57. Malone, T.C.; Ortwine, D.F.; Johnson, G.; Probert, A.W. Jr. Synthesis and biological activity of conformationally constrained 4a-phenanthreneamine derivatives as noncompetitive NMDA antagonists. Bioorg. Med. Chem. Lett., 1993, 3, 49-54.
58. (a) Lamanec, T.R.; Bender, D.R.; DeMarco, A.M.; Karady, S.; Reamer, R.A.; Weinstock, L.M. α -Effect nucleophiles: a novel and convenient method for the synthesis of dibenzo[a,d]cycloheptenimines. J. Org. Chem., 1988, 53, 1768-1774;
59. (b) Anderson, P. S.; Christy, M. E.; Evans, B. E. 5-Substituted 10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imines. Ger. Offen., 1979 DE2840786;
60. (c) Anderson, P. S.; Christy, M. E.; Evans, B. E. 5-Alkyl or hydroxyalkyl substituted-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imines and their anticonvulsant use. U.S. Patent, 1983, US 4,399,141.
61. Kalir, A.; Edery, H.; Pelah, Z.; Balderman, D.; Porath, G. 1-Phenylcycloalkylamine derivatives. II. Synthesis and pharmacological activity. J. Med. Chem., 1969, 12, 473-477.
62. Naqvi, S.M.; Horwitz, J.P.; Filler, R. Rearrangement of cyclohexene oxides with magnesium bromide etherate. J. Am. Chem. Soc., 1957, 79, 6283-6286.